H.C. Wainwright raised the firm’s price target on BioCryst (BCRX) to $32 from $30 and keeps a Buy rating on the shares. The firm cites the approval of Orladeyo in the pediatric patient population for the target bump. Orladeyo is the first and only targeted oral prophylactic therapy approved for use in patients ages two to 12 with hereditary angioedema, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
- BioCryst’s Growth Potential Bolstered by FDA Approval and Strategic Moves: A Buy Recommendation
- BioCryst Gains FDA Approval for Pediatric HAE Drug
- BioCryst announces FDA approved NDA for of ORLADEYO